State of the Landscape: MedTech, Diagnostics & Digital Health landscape in the first half of 2026

In this update, we explore the European investment landscape across MedTech, Diagnostics and Digital Health in the first half of 2026. 

Early-stage activity remained resilient, while larger growth rounds increased capital deployment. Digital Health continued to lead, but investment broadened across in vitro diagnostics, diagnostic imaging and neurology. 

We also examine two early-stage companies that reflect wider investment trends in AI diagnostics and cell and gene therapy manufacturing.